{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:02:38Z","timestamp":1790650958912,"version":"4.1.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"DOI":"10.1182\/bloodadvances.2022008068","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T17:04:44Z","timestamp":1665162284000},"page":"4760-4764","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Real-world prognostic testing and treatment patterns in CLL\/SLL: results from 1462 patients in the informCLL registry"],"prefix":"10.1182","volume":"7","author":[{"given":"Anthony R.","family":"Mato","sequence":"first","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"2Levine Cancer Institute, Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"3Willamette Valley Cancer Institute & Research Center, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Brander","sequence":"additional","affiliation":[{"name":"4Duke University Health System, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"5Lymphoma Research Foundation, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-7591","authenticated-orcid":false,"given":"Qing","family":"Huang","sequence":"additional","affiliation":[{"name":"6Janssen Scientific Affairs, LLC, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda H.","family":"Wu","sequence":"additional","affiliation":[{"name":"6Janssen Scientific Affairs, LLC, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Young","sequence":"additional","affiliation":[{"name":"7Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Upasani","sequence":"additional","affiliation":[{"name":"7Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoko","family":"Naganuma","sequence":"additional","affiliation":[{"name":"7Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-5535","authenticated-orcid":false,"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[{"name":"8Mount Sinai Medical Center, Miami Beach, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"issue":"1","key":"2023091114435327100_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/asheducation-2018.1.248","article-title":"Relapsed CLL: sequencing, combinations, and novel agents","volume":"2018","author":"Brown","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2023091114435327100_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11899-020-00584-3","article-title":"Utilizing real-world evidence (RWE) to improve care in chronic lymphocytic leukemia: challenges and opportunities","volume":"15","author":"Islam","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"2023091114435327100_bib3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023091114435327100_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023091114435327100_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023091114435327100_bib6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023091114435327100_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/2159-8290.CD-19-1130","article-title":"Acalabrutinib plus obinutuzumab in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia","volume":"10","author":"Woyach","year":"2020","journal-title":"Cancer Discov"},{"issue":"25","key":"2023091114435327100_bib8","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and\u00a0supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2023091114435327100_bib9","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"9747","key":"2023091114435327100_bib10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"2023091114435327100_bib11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clml.2019.10.009","article-title":"Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry","volume":"20","author":"Mato","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2023091114435327100_bib12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"26","key":"2023091114435327100_bib13","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023091114435327100_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023091114435327100_bib15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 5","key":"2023091114435327100_bib16","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4760\/2076950\/blooda_adv-2022-008068-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4760\/2076950\/blooda_adv-2022-008068-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T14:44:09Z","timestamp":1694443449000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/4760\/486742\/Real-world-prognostic-testing-and-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":16,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008068","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}